Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Post by Scorpio2on Dec 01, 2018 11:06am
94 Views
Post# 29049289

Two CEO's

Two CEO'sI think the reality and the driving force is firstly, to have two divisions as the cancer division will attract a higher PE multiple in a buyout than would the merged company with the laser division that would attract a lower PE multiple as the laser division itself would attract a lower multiple. The end objective for all parties here is an eventual buyout.

Secondly, any entity that we get into bed with is going to want their guy at the head of the cancer division with a singular focus on that aspect. I think the CEO will not be an external hire and possibly the low salary is to discourage outside people from applying. When this puppy gets market acceptance and gets off the ground, just think of the operational activity that is going to be involved with transitioning TLT and their " new disruptive cancer solution" into the new entity and the marketplace. TLT's people (over a transition period), process and technology will not change but the execution will need to consider implementing TLT's solution on a large scale and globally. Think, marketing, media, legal, sales, operations, billings,  controls, training, etc. etc.     
Bullboard Posts